...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Hyperfibrinolysis increases blood-brain barrier permeability by a plasmin- and bradykinin-dependent mechanism
【24h】

Hyperfibrinolysis increases blood-brain barrier permeability by a plasmin- and bradykinin-dependent mechanism

机译:高纤蛋白溶解通过纤溶酶和缓激肽依赖性机制增加血脑屏障通透性

获取原文
获取原文并翻译 | 示例

摘要

Hyperfibrinolysis is a systemic condition occurring in various clinical disorders such as trauma, liver cirrhosis, and leukemia. Apart from increased bleeding tendency, the pathophysiological consequences of hyperfibrinolysis remain largely unknown. Our aim was to develop an experimental model of hyperfibrinolysis and to study its effects on the homeostasis of the blood-brain barrier (BBB). We induced a sustained hyperfibrinolytic state in mice by hydrodynamic transfection of a plasmid encoding for tissue-type plasminogen activator (tPA). As revealed by near-infrared fluorescence imaging, hyperfibrinolytic mice presented a significant increase in BBB permeability. Using a set of deletion variants of tPA and pharmacological approaches, we demonstrated that this effect was independent of N-methyl-D-aspartate receptor, low-density lipoprotein-related protein, protease-activated receptor-1, or matrix metall oproteinases. In contrast, we provide evidence that hyperfibrinolysis-induced BBB leakage is dependent on plasmin-mediated generation of bradykinin and subsequent activation of bradykinin B2 receptors. Accordingly, this effect was prevented by icatibant, a clinically available B2 receptor antagonist. In agreement with these preclinical data, bradykinin generation was also observed in humans in a context of acute pharmacological hyperfibrinolysis. Altogether, these results suggest that B2 receptor blockade may be a promising strategy to prevent the deleterious effects of hyperfibrinolysis on the homeostasis of the BBB.
机译:高纤维蛋白溶解是一种全身性疾病,发生在各种临床疾病中,例如创伤,肝硬化和白血病。除了增加的出血倾向外,高纤蛋白溶解的病理生理后果仍然未知。我们的目的是开发一种高纤蛋白溶解的实验模型,并研究其对血脑屏障(BBB)稳态的影响。我们通过流体动力学转染编码组织型纤溶酶原激活物(tPA)的质粒,在小鼠中诱导了持续的高纤蛋白溶解状态。如近红外荧光成像所揭示,超纤溶小鼠的血脑屏障通透性显着增加。使用一组tPA的缺失变体和药理学方法,我们证明了这种作用不依赖于N-甲基-D-天冬氨酸受体,低密度脂蛋白相关蛋白,蛋白酶激活受体-1或基质金属蛋白酶。相反,我们提供的证据表明,高纤蛋白溶解诱导的BBB泄漏取决于纤溶酶介导的缓激肽的产生以及缓激肽B2受体的后续活化。因此,这种效果被临床上可用的B2受体拮抗剂icatibant阻止。与这些临床前数据一致,在急性药理性高纤维蛋白溶解的背景下,在人中也观察到了缓激肽的产生。总之,这些结果表明,B2受体阻滞可能是防止高纤蛋白溶解对BBB体内稳态的有害作用的有前途的策略。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号